Glucagon-like peptide 1 receptor agonists (GLP-1RAs) prescribed for type 2 diabetes are associated with reduced colorectal cancer (CRC) risk compared to other antidiabetic agents
1. In all patients, there was a 44% reduction in risk of colorectal cancer when using GLP-1RAs as compared to ...